Cost-Effectiveness of a Novel Treatment for Cancer-Associated Thrombosis (CAT): Results from an Early Economic Analysis


Ellis A1, Bloomfield D2, Mehta N2, Yi BA2, Khder Y3
1Stratevi, Boston, MA, USA, 2Anthos Therapeutics, Cambridge, MA, USA, 3MYRA Life Science Services, Basel, Switzerland

OBJECTIVES: Direct oral anticoagulants and low-molecular weight heparins have demonstrated to be effective in preventing or treating cancer-associated thrombosis (CAT), but they also interfere with hemostasis leading to an increased risk of bleeding and decreased adherence. As a result, many patients with CAT do not receive adequate treatment in terms of dose and/or duration, which can lead to less favorable outcomes. This early economic analysis explored the potential cost-effectiveness of a hypothetical new therapy for the treatment of CAT from a UK perspective.

METHODS: A Markov model was developed to reflect the clinical pathways typical of patients with CAT. Use of a hypothetical new treatment was compared with apixaban and dalteparin. Treatment discontinuation for apixaban and dalteparin was informed by real-world discontinuation rates. A plausible range of bleeding risk for the new treatment was assessed. Total costs and quality-adjusted life years over a lifetime were compared.

RESULTS: Compared to apixaban, a new treatment that reduced the risk of bleeding by at least 23% was cost-effective at a £30k/QALY threshold assuming a monthly cost that is 20% higher than apixaban, the same risk for venous thromboembolisms, and a 30% lower discontinuation rate. Considering a range between 0.5-0.7 for the relative risk of bleeding versus apixaban, the new treatment remained cost-effective with a monthly cost up to 28-53% higher than apixaban. The new treatment dominated dalteparin in all scenarios explored.

CONCLUSIONS: An effective treatment that reduces the risk of bleeding and offers improved adherence is a potentially cost-effective treatment option for patients with CAT. The model results suggest that a treatment with these characteristics could both improve outcomes in patients with CAT while also demonstrating economic value.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)




Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis


STA: Drugs

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now